JAMA

DENSO to Exhibit at JAPAN MOBILITY SHOW 2023

Retrieved on: 
Monday, October 16, 2023
QR code, SOEC, World Future Society, Tokyo Big Sight, Music, Japan Automobile Manufacturers Association, Happiness, PEM, Electricity, DENSO, JAMA, AR, Imagination, Electrolysis, Toyota, Child, Hydrogen, Reading, Water, Online shopping, Nightclub

KARIYA, JAPAN, Oct 16, 2023 - (JCN Newswire) - DENSO CORPORATION today announced that it will exhibit at JAPAN MOBILITY SHOW 2023(1), held at Tokyo Big Sight, from Saturday, October 28 to Sunday, November 5.At its booth, DENSO will present stories about how it hopes to contribute to the happiness of people in the future with mobility under the theme, "The Future Society Envisioned by DENSO through Its Imagination and Technology."

Key Points: 
  • KARIYA, JAPAN, Oct 16, 2023 - (JCN Newswire) - DENSO CORPORATION today announced that it will exhibit at JAPAN MOBILITY SHOW 2023(1), held at Tokyo Big Sight, from Saturday, October 28 to Sunday, November 5.At its booth, DENSO will present stories about how it hopes to contribute to the happiness of people in the future with mobility under the theme, "The Future Society Envisioned by DENSO through Its Imagination and Technology."
  • It will display DENSO products intended to help create a better life for people in future society, where new types of mobility and technology preserve the global environment.
  • For more details of the DENSO booth, please visit DENSO's special website for Japan Mobility Show 2023 at: https://www.denso.com/global/en/events/japan-mobility-show/2023/
    Moreover, the organizer's program called "Tokyo Future Tour" on the 1st floor of the West Exhibition Building, shows how Tokyo will change in the future with new types of mobility.
  • Reference: Japan Mobility Show 2023 Official Website, https://www.japan-mobility-show.com/en/

Naveris Announces Two Peer-Review Publications Validating NavDx® Performance in Daily Clinical Practice

Retrieved on: 
Thursday, October 12, 2023
Radiology, Health, Surgery, Oncology, Diagnosis, Neoplasm, TTMV, Physician, Ferrandino, Doctor of Philosophy, Research, Dana–Farber Cancer Institute, MD, DNA, CCR, Recurrence, Disease, Human, JAMA, HPV, Literature, Clinical Cancer Research, MRD, Liquid biopsy, OPSCC, Patient, Vaccine

Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance (Hanna, G.J.

Key Points: 
  • Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance (Hanna, G.J.
  • ), published in CCR, is a retrospective observational cohort study involving 543 patients who completed therapy for HPV-driven oropharyngeal squamous cell carcinoma (OPSCC).
  • “NavDx has consistently exhibited stellar performance in well over a dozen peer-reviewed studies following thousands of HPV-driven OPSCC patients.
  • “We congratulate these investigators on their outstanding research, and look forward to our ongoing partnerships with the clinical research community to support bringing NavDx testing to more patients.”

DENSO to Exhibit at JAPAN MOBILITY SHOW 2023

Retrieved on: 
Monday, October 16, 2023
QR code, SOEC, World Future Society, Tokyo Big Sight, Music, Japan Automobile Manufacturers Association, Happiness, PEM, Electricity, DENSO, Water, JAMA, JAPAN, AR, Imagination, Electrolysis, Toyota, Child, Hydrogen, Reading, Nightclub, Entertainment

KARIYA, Japan, Oct. 16, 2023 /PRNewswire/ -- DENSO CORPORATION today announced that it will exhibit at JAPAN MOBILITY SHOW 2023*¹, held at Tokyo Big Sight, from Saturday, October 28 to Sunday, November 5.

Key Points: 
  • KARIYA, Japan, Oct. 16, 2023 /PRNewswire/ -- DENSO CORPORATION today announced that it will exhibit at JAPAN MOBILITY SHOW 2023*¹, held at Tokyo Big Sight, from Saturday, October 28 to Sunday, November 5.
  • At its booth, DENSO will present stories about how it hopes to contribute to the happiness of people in the future with mobility under the theme, "The Future Society Envisioned by DENSO through Its Imagination and Technology."
  • The T-shirts of DENSO booth staff are made from materials recycled from discarded work uniforms of different companies including DENSO.
  • For more details of the DENSO booth, please visit DENSO's special website for Japan Mobility Show 2023 at: https://www.denso.com/global/en/events/japan-mobility-show/2023/ .

Large Clinical Trial by the Centers for Disease Control and Prevention, Harvard Pilgrim Health Care Institute, HCA Healthcare and UCI Health Identifies Best Strategy to Prevent Life-Threatening Health Care-Associated ICU Infections

Retrieved on: 
Tuesday, October 10, 2023
Research, Hospitals, Clinical Trials, Health Insurance, Other Health, Managed Care, Health, Pharmaceutical, Science, Chlorhexidine, JAMA, Multimedia, Hospital, Harvard Medical School, Bloodstream infections, Health care, Division, Mupirocin, Suggestion, Bacteria, University of California, Irvine Medical Center, Master of Science, Risk, Intensive care unit, CDC, Antimalarial medication, University, Infection, American Medical Association, CHG, MRSA, Journal, Povidone-iodine, University of California, Irvine School of Medicine, Staphylococcus aureus, REDUCE, Nose, ICU, Additive effect, HCA Healthcare, Korea Disease Control and Prevention Agency, Skin, ABATE, Patient, Harvard Pilgrim Health Care, Pharmaceutical industry, Nursing, MD, Medicine

This strategy is called “decolonization” because it reduces the amount of bacteria on the body in order to reduce infection risk.

Key Points: 
  • This strategy is called “decolonization” because it reduces the amount of bacteria on the body in order to reduce infection risk.
  • The Mupirocin-Iodophor Swap Out Trial directly compared nasal mupirocin to nasal iodophor in the context of chlorhexidine bathing.
  • “This study further supports CDC guidance on using a strategy that combines nasal decolonization plus CHG bathing in ICU patients.
  • The results resolved the question about whether nasal treatment is necessary in addition to chlorhexidine bathing to prevent these ICU infections.

Alimentiv Inc. Announces New Scientific Advisors Leading Research In GI-Related Therapeutics

Retrieved on: 
Friday, October 13, 2023
Mount Sinai, Icahn School of Medicine at Mount Sinai, Contract research organization, Internal medicine, MS, Abstract, Research, VARSITY, The New England Journal of Medicine, Crohn's and Colitis Canada, Therapy, IBD, Safety, University, Inflammatory bowel disease, Annals of Internal Medicine, JAMA, Inflammatory Bowel Diseases, Publication, United States Army Medical Research and Development Command, Dean, Patient, Pharmaceutical industry, MD, Nature, Medicine, Lancet

LONDON, ON, Oct. 13, 2023 /PRNewswire/ - Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.

Key Points: 
  • LONDON, ON, Oct. 13, 2023 /PRNewswire/ - Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.
  • The advisors are internationally recognized experts in designing and conducting clinical research in Inflammatory Bowel Disease.
  • Their contributions to the field have been essential in progressing the development of novel therapies in IBD and improving patient outcomes.
  • He holds the Crohn's Colitis Canada Endowed Research Chair in Inflammatory Bowel Disease and is an executive member of the IOIBD.

Alimentiv Inc. Announces New Scientific Advisors Leading Research In GI-Related Therapeutics

Retrieved on: 
Friday, October 13, 2023
Mount Sinai, Icahn School of Medicine at Mount Sinai, Contract research organization, Internal medicine, MS, Abstract, Research, VARSITY, The New England Journal of Medicine, Crohn's and Colitis Canada, Therapy, IBD, Safety, University, Inflammatory bowel disease, Annals of Internal Medicine, JAMA, Inflammatory Bowel Diseases, Publication, United States Army Medical Research and Development Command, Dean, Patient, Pharmaceutical industry, MD, Nature, Medicine, Lancet

LONDON, ON, Oct. 13, 2023 /PRNewswire/ -- Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.

Key Points: 
  • LONDON, ON, Oct. 13, 2023 /PRNewswire/ -- Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.
  • The advisors are internationally recognized experts in designing and conducting clinical research in Inflammatory Bowel Disease.
  • Their contributions to the field have been essential in progressing the development of novel therapies in IBD and improving patient outcomes.
  • He holds the Crohn's Colitis Canada Endowed Research Chair in Inflammatory Bowel Disease and is an executive member of the IOIBD.

Highmark Health and Spring Health Collaborate to Launch My Highmark's Mental Well-Being Powered by Spring Health

Retrieved on: 
Monday, October 9, 2023
Well, Health, Language, United, ADHD, Doctor of Philosophy, Spring, Bipolar disorder, PTSD, MPH, DSM-IV codes, Mental health, Eating, JAMA, FCC, Mental, Tic disorder, OCD, Post-traumatic stress disorder, Overalls, Factitious disorder, Nursing, Highmark, MD

LAS VEGAS, Oct. 9, 2023 /PRNewswire/ -- Highmark Health and Spring Health today announced their collaboration to expand the number of access points to behavioral health care by 40 percent for Highmark insurance members, including children and teens. Highmark's Mental Well-Being powered by Spring Health will offer multiple levels of support: digital capabilities for daily wellness, one-on-one care navigation, deeper clinical care through in-person or virtual therapy, medication management, and 24/7 crisis support.

Key Points: 
  • "Together, Highmark Health and Spring Health are advancing the future state of mental and behavioral health," said Anil Singh, MD, MPH, FCC, senior vice president, executive medical director of population and curated health, Highmark Health.
  • Mental Well-Being is powered by Spring Health, the most comprehensive global mental health solution for employers and health plans, and provides members with access to therapy and medication management appointments in an average of three days or less.
  • "Spring Health's precision technology is changing the mental health paradigm," said Adam Chekroud, PhD, president and co-founder, Spring Health.
  • Mental Well-Being powered by Spring Health will be available to health plan members through the My Highmark member platform.

HiLabs' AI engine processes clinical data 100x faster than humans, unlocks unused data

Retrieved on: 
Thursday, October 5, 2023
University of Colorado School of Medicine, Health, Multimedia, University, JAMA, Assistant, Human, Patient, CO, Medical device, Nursing, Casino

BETHESDA, Md., Oct. 5, 2023 /PRNewswire/ -- HiLabs' AI-powered engine, MCheck, proves capable of ingesting, indexing, and summarizing clinical data 100 times faster than humans, building on the engine's capabilities in provider data recently published in JAMA.

Key Points: 
  • BETHESDA, Md., Oct. 5, 2023 /PRNewswire/ -- HiLabs' AI-powered engine, MCheck, proves capable of ingesting, indexing, and summarizing clinical data 100 times faster than humans, building on the engine's capabilities in provider data recently published in JAMA.
  • Cleans clinical and supplemental data 100x faster than human operators.
  • Clinical data contains enormous potential to uncover patient insights and improve health on a population level.
  • HiLabs' AI engine, MCheck, successfully completed the complex task of standardizing such clinical and supplemental data sources for a national health plan at a rate 100 times faster than their current labor-intensive operations.

Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization

Retrieved on: 
Wednesday, October 4, 2023
Seizure, Cardiac muscle, Progress, DSM-IV codes, American Medical Association, Journal, Patient, Division, ASO, Neurology, Disease, Columbia University, Tissue, Hypertriglyceridemia, Dementia, Small RNA, Ionis Pharmaceuticals, PDUFA, Pelizaeus–Merzbacher disease, FDA, FCS, Safety, Therapeutic index, Development, Alexander disease, IONS, MECP2, Medicine, HAE, MPH, JAMA, PLP1, Hereditary angioedema, Traffic barrier, RNA, AstraZeneca, Leukodystrophy, Delivery, Phase 3, Physician, World Creativity and Innovation Day, Vaccine, Pharmaceutical industry, Medical device, Residential care, Ionis, EU, ATTR

Presentations from Ionis leaders and external physicians will highlight Ionis' comprehensive integrated research, development, and commercialization capabilities, along with key pipeline and technology highlights.

Key Points: 
  • Presentations from Ionis leaders and external physicians will highlight Ionis' comprehensive integrated research, development, and commercialization capabilities, along with key pipeline and technology highlights.
  • "Our powerful and prolific research and development engine has discovered groundbreaking medicines for people with devastating diseases.
  • We have matched this engine with a talented commercial organization poised to deliver a steady flow of wholly owned medicines to patients.
  • The event will take place at the Westin New York Grand Central from 8:00 a.m. to 3:00 p.m. Eastern Time and will also be webcast.

HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Retrieved on: 
Friday, September 29, 2023
Priority review, CRC, Progression-free survival, TAK, European Medicines Agency, JAMA, NDA, Ministry of Health, Labour and Welfare, Woman, EMA, American Medical Association, Ministry, Incidence, HKEX, Journal, Prescription Drug User Fee Act, Patient, PDUFA, Federal Ministry of Health (Germany), BSC, Mortality, MAA, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Takeda, Health, Lancet

Fruquintinib is a selective inhibitor of vascular endothelial growth factor receptors (“VEGFR”) -1, -2 and -3, which play a pivotal role in blocking tumor angiogenesis.

Key Points: 
  • Fruquintinib is a selective inhibitor of vascular endothelial growth factor receptors (“VEGFR”) -1, -2 and -3, which play a pivotal role in blocking tumor angiogenesis.
  • The FRESCO-2 and FRESCO clinical trials compared fruquintinib plus best supportive care (“BSC”) with placebo plus BSC in patients with previously treated metastatic CRC.
  • The U.S. Food and Drug Administration (“FDA”) granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of November 30, 2023.
  • A Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) was validated and accepted for regulatory review in June 2023.